The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Jan Nilsson

Professor

Default user image.

Oxidized LDL antibodies in treatment and risk assessment of atherosclerosis and associated cardiovascular disease.

Author

  • Jan Nilsson
  • Gunilla Nordin Fredrikson
  • Alexandru Schiopu
  • Prediman K Shah
  • Bo Jansson
  • Roland Carlsson

Summary, in English

Immune responses against oxidized forms of LDL play a critical role in activation and regulation of the inflammatory process that characterizes all stages of atherosclerosis. In humans oxidized LDL is targeted by both IgM and IgG autoantibodies. Immunization of hypercholesterolemic animals with oxidized LDL has been shown to inhibit atherosclerosis demonstrating that at least some of these immune responses have a protective effect. The identification of the structures in oxidized LDL that are responsible for activation of immunity has made it possible to develop novel therapeutic approaches for treatment of atherosclerosis based on active (vaccines) and passive (antibodies) immunization. Studies performed in atherosclerosis-prone mice demonstrate that both peptide-based vaccines and recombinant IgG targeting epitopes in oxidized LDL significantly reduce atherosclerosis. There is also evidence antibodies against oxidized LDL could also be used for imaging atherosclerosis.

Department/s

  • Cardiovascular Research - Immunity and Atherosclerosis
  • Department of Clinical Sciences, Lund
  • Tumor microenvironment
  • Department of Immunotechnology

Publishing year

2007

Language

English

Pages

1021-1030

Publication/Series

Current Pharmaceutical Design

Volume

13

Issue

10

Document type

Journal article review

Publisher

Bentham Science Publishers

Topic

  • Clinical Medicine

Status

Published

Research group

  • Cardiovascular Research - Immunity and Atherosclerosis

ISBN/ISSN/Other

  • ISSN: 1381-6128